What You Should Know:
– Creyos, the digital platform reshaping brain health assessment in clinical care, has expanded its Session Notes feature to support structured assessment protocols commonly used in the evaluation of cognitive function related to conditions like dementia.
– The addition of session notes to protocols is designed to help close the gap in detection by turning cognitive screening and assessment results into structured, clinically relevant, documentation.
Creyos Enhances Cognitive Health Documentation for Faster, More Accurate Primary Care Decisions
Scientifically Validated Platform for Brain Health Assessment
Creyos—formerly Cambridge Brain Sciences—is a leading healthcare technology company transforming how clinicians assess, monitor, and manage patient brain health. The FDA-registered platform, backed by over 30 years of neuroscience research and a normative database of 85,000+ participants, includes objective online tasks, digital behavioral health screeners, and condition-specific assessments. Validated in more than 400 peer-reviewed studies, Creyos supports evidence-based decisions for conditions such as dementia, ADHD, depression, anxiety, and other cognitive and behavioral health concerns.
Providers can integrate Creyos directly into existing workflows, with structured, editable notes that summarize key insights from patient cognitive performance. These notes can be reviewed and inserted into the EHR in seconds—reducing documentation time, providing objective proof for clinical decisions, and enabling consistent, actionable next steps in care. The platform supports referrals, billing, and care planning, ensuring seamless adoption for health systems and clinicians.
Addressing the Cognitive Care Gap in Primary Care
The launch of the expanded Session Notes feature comes as the U.S. faces a surge in dementia-related challenges driven by an aging population. CMS now requires cognitive screening during Medicare Annual Wellness Visits, yet primary care providers often lack the time, tools, and resources to conduct and document assessments effectively. Value-based care models reward timely, accurate detection, but specialist shortages and workflow constraints leave many patients undiagnosed or waiting for clarity—resulting in missed treatment opportunities.
“We expanded our Session Notes feature in direct response to what we heard from primary care teams,” said Faraz Shafaghi, Chief Product Officer at Creyos. “They’re facing tight visit times and rising cognitive health concerns with no easy way to document it all. This feature turns cognitive data into immediate next steps, operationalizing brain health in the reality of primary care.”
For full risk-bearing organizations managing Medicare Advantage populations, accurate and timely documentation of cognitive impairment is critical—not only for clinical care but also for reimbursement, compliance, and care coordination. The Creyos platform provides the structured, evidence-backed tools needed to assess and document cognitive decline consistently across diverse care settings.
Founded on the pioneering research of Professor Adrian Owen, Chief Scientific Officer and co-founder, Creyos continues to advance the understanding of cognition, consciousness, and early decline. Used widely in neurology, mental health, and senior care, the platform enables proactive screening and monitoring for a spectrum of cognitive and behavioral conditions—helping providers bridge the gap between detection and effective intervention.
